A recent analysis found that type 2 diabetes treatment using incretin-based therapies was not associated with an increased risk of heart failure. Canadian researchers came to this conclusion after studying a cohort of nearly 1.5 million patients in the UK, U.S., and Canada.
Within this group, the incidence of hospitalizations due to heart failure was 9.2 events per 1,000 people each year. The rate of hospitalization for heart failure did not increase when incretin-based therapies were used instead of oral antidiabetic combinations with patients with a history of heart failure. Additionally, there was not a greater risk for patients with no previous history of heart failure.
These findings were published in the New England Journal of Medicine on March 24, 2016.